INS and obesity disorder: Diazoxide, being an effective agonist of ATP-sensitive K+ channels (KATP), inhibits insulin production and regulates the ability of skeletal muscle to take up glucose; it is a drug used in the treatment of dyslipidemia and obesity [13] since it decreases food consumption and body weight [14], improves fatty acid oxidation and decreases fat storage in the form of adipose tissue [13].